X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): M102
Therapeutic Area: Neurology Product Name: M102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medical Research Council (U.K)
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2021
Details:
The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.
Lead Product(s): M102
Therapeutic Area: Neurology Product Name: M102
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: FightMND
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
